Amiravo: Peptide Research & Dosing Reference
Compounds
Guides
-
Molarity, explained
-
Reading a peptide label: FDA prescription labeling versus a research-use-only vial
-
The thymosin family: thymosin alpha-1, thymosin beta-4 and TB-500
-
Why so much peptide evidence comes from animals, and how to read it
-
How peptides are engineered to last longer in the body
-
GLP-1, GIP and glucagon: from single to dual to triple agonists
-
From Gila monster venom to weekly injections: a short history of GLP-1 drugs
-
Peptide stability basics
-
What “research use only” means
-
Planning supply for an experiment
-
Peptide legality in the United States: research use only, approval and compounding
-
Dilution, explained (C1V1 = C2V2)
-
How to read a certificate of analysis
-
Lab units and conversions
-
What is a peptide?
-
Storage and handling basics for lyophilized material
-
How we label the evidence
-
Reconstitution math, explained
-
Reading a research vial label
-
Purity testing explained: HPLC, mass spectrometry, endotoxin and net peptide content
-
Khavinson peptide bioregulators: what the research is and how strong it is
-
What FDA warning letters to peptide sellers say
-
FDA's 2025-2026 review of peptides for compounding
-
Why most peptides are injected: oral, nasal and topical delivery
-
Testing laboratories and test panels: accreditation, USP methods and screens
-
How peptides are made: solid-phase synthesis, impurities and what "pharmaceutical grade" means
-
The incretin pipeline in 2026: dual and triple agonists, amylin combinations and oral agents
-
Amylin and amylin analogs explained
-
Myths and misconceptions about peptides
-
What are peptide blends? Reading component lists such as KLOW and GLOW
-
Topical cosmetic peptides versus research and drug peptides
-
Shipping and transporting research materials: regulatory considerations
-
Peptides and sport: how the WADA Prohibited List treats peptide compounds
-
How to read a clinical trial and how Amiravo's A-D evidence grades work
-
FDA in 2026: telehealth GLP-1 letters and a line on retatrutide
-
CagriSema in 2026: head-to-head results and a pending FDA decision
-
Lilly files six lawsuits against US retatrutide sellers
-
Retatrutide: Lilly reports TRIUMPH-2 and TRIUMPH-3 phase 3 results